Noah Goodman Sells 2,500 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Noah Goodman sold 2,500 shares of the stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $99.00, for a total value of $247,500.00. Following the completion of the transaction, the insider directly owned 50,195 shares in the company, valued at approximately $4,969,305. This represents a 4.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Noah Goodman also recently made the following trade(s):

• On Tuesday, April 14th, Noah Goodman sold 1,347 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.00, for a total value of $121,230.00.
• On Friday, April 10th, Noah Goodman sold 2,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $87.35, for a total transaction of $174,700.00.
• On Thursday, April 9th, Noah Goodman sold 8,264 shares of Kymera Therapeutics stock. The shares were sold at an average price of $87.50, for a total transaction of $723,100.00.

Kymera Therapeutics Price Performance

Shares of NASDAQ:KYMR traded up $9.02 during trading on Monday, hitting $99.45. The company’s stock had a trading volume of 2,891,041 shares, compared to its average volume of 688,878. The firm has a market cap of $8.18 billion, a price-to-earnings ratio of -27.86 and a beta of 2.02. The company has a 50-day moving average of $83.16 and a 200-day moving average of $81.06. Kymera Therapeutics, Inc. has a 12 month low of $36.65 and a 12 month high of $105.00.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The company had revenue of $34.37 million during the quarter, compared to analyst estimates of $8.27 million. During the same period in the previous year, the business posted ($0.82) earnings per share. The firm’s quarterly revenue was up 55.5% compared to the same quarter last year. As a group, research analysts anticipate that Kymera Therapeutics, Inc. will post -3.25 earnings per share for the current year.

Analyst Ratings Changes

KYMR has been the topic of a number of recent research reports. Jefferies Financial Group started coverage on Kymera Therapeutics in a report on Monday, March 16th. They issued a “buy” rating and a $110.00 target price on the stock. Loop Capital set a $97.00 price target on Kymera Therapeutics in a report on Monday, June 8th. Wall Street Zen upgraded Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $108.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, February 26th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $117.14.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. US Bancorp DE increased its holdings in shares of Kymera Therapeutics by 9.8% in the 3rd quarter. US Bancorp DE now owns 1,865 shares of the company’s stock worth $106,000 after buying an additional 166 shares during the last quarter. Glenmede Trust Co. NA increased its stake in Kymera Therapeutics by 3.6% during the first quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock worth $565,000 after acquiring an additional 235 shares during the last quarter. Cetera Investment Advisers increased its stake in Kymera Therapeutics by 7.5% during the first quarter. Cetera Investment Advisers now owns 3,602 shares of the company’s stock worth $300,000 after acquiring an additional 252 shares during the last quarter. Larson Financial Group LLC raised its position in Kymera Therapeutics by 36.9% during the fourth quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock valued at $83,000 after purchasing an additional 287 shares during the period. Finally, Swiss National Bank raised its position in Kymera Therapeutics by 0.3% during the first quarter. Swiss National Bank now owns 94,500 shares of the company’s stock valued at $7,871,000 after purchasing an additional 300 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.